NCS-1, a calcium-binding protein recently identified as a binding partner of paclitaxel,6 influences the biological effects of this drug in vitro7 and is associated with poor clinical outcome in breast cancer.8 Our in vitro studies further demonstrated that overexpression of NCS-1 increased the efficacy of paclitaxel.8 The gene discussed is NCS1; the disease is breast carcinoma.